Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

Leukemia Research

Volumn 38, Issue 9, 2014, Pages 1126-1129

  Daver, Naval ^a   Shastri, Aditi ^a,b   Kadia, Tapan ^a   Newberry, Kate ^a   Pemmaraju, Naveen ^a   Jabbour, Elias ^a   Zhou, Linghsa ^a   Pierce, Sherry ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Anemia; Myelofibrosis; Pomalidomide

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ANAGRELIDE; DANAZOL; HYDROXYUREA; LENALIDOMIDE; PEGINTERFERON; POMALIDOMIDE; PREDNISONE; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BLOATING; BLURRED VISION; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; FOLLOW UP; FOOT EDEMA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTHYROIDISM; LOW DRUG DOSE; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; MYELOFIBROSIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SPLENOMEGALY; TREATMENT OUTCOME; URINARY FREQUENCY; VERY ELDERLY;

ANEMIA; MYELOFIBROSIS; POMALIDOMIDE;

AGED; AGED, 80 AND OVER; ANEMIA; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDNISONE; PRIMARY MYELOFIBROSIS; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84906934354     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.06.015     Document Type: Article

References (24)

1. Spivak J.L. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 2004, 41:1-5.
2. Cervantes F., Dupriez B., Pereira A., Passamonti F., Reilly J.T., Morra E., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113:2895-2901.
3. Emanuel R.M., Dueck A.C., Geyer H.L., Kiladjian J.J., Slot S., Zweegman S., et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012, 30:4098-4103.
4. Mesa R.A., Niblack J., Wadleigh M., Verstovsek S., Camoriano J., Barnes S., et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007, 109:68-76.
5. Huang J., Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009, 83:154-155.
6. Cervantes F., Alvarez-Larran A., Domingo A., Arellano-Rodrigo E., Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005, 129:771-775.
7. Verstovsek S., Kantarjian H., Mesa R.A., Pardanani A.D., Cortes-Franco J., Thomas D.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010, 363:1117-1127.
8. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366:799-807.
9. Thomas D.A., Giles F.J., Albitar M., Cortes J.E., Verstovsek S., Faderl S., et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006, 106:1974-1984.
10. Marchetti M., Barosi G., Balestri F., Viarengo G., Gentili S., Barulli S., et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004, 22:424-431.
11. Mesa R.A., Steensma D.P., Pardanani A., Li C.Y., Elliott M., Kaufmann S.H., et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003, 101:2534-2541.
12. Quintas-Cardama A., Kantarjian H.M., Manshouri T., Thomas D., Cortes J., Ravandi F., et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009, 27:4760-4766.
13. Tefferi A., Cortes J., Verstovsek S., Mesa R.A., Thomas D., Lasho T.L., et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006, 108:1158-1164.
14. Tefferi A., Verstovsek S., Barosi G., Passamonti F., Roboz G.J., Gisslinger H., et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009, 27:4563-4569.
15. Tefferi A., Barosi G., Mesa R.A., Cervantes F., Deeg H.J., Reilly J.T., et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006, 108:1497-1503.
16. Tefferi A., Passamonti F., Barbui T., Barosi G., Begna K., Cazzola M., et al. Phase 3 Study of Pomalidomide in Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis with RBC-Transfusion-Dependence 2013, American Society of Hematology, New Orleans.
17. Daver N., Shastri A., Kadia T., Quintas-Cardama A., Jabbour E., Konopleva M., et al. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res 2013, 37:1440-1444.
18. Begna K.H., Mesa R.A., Pardanani A., Hogan W.J., Litzow M.R., McClure R.F., et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011, 25:301-304.
19. Mesa R.A., Pardanani A.D., Hussein K., Wu W., Schwager S., Litzow M.R., et al. Phase1/-2 study of pomalidomide in myelofibrosis. Am J Hematol 2010, 85:129-130.
20. Begna K.H., Pardanani A., Mesa R., Litzow M.R., Hogan W.J., Hanson C.A., et al. Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol 2012, 87:66-68.
21. Vardiman J.W.B.R., Harris N.L. WHO histological classification of chronic myeloproliferative diseases. World Health Organization Classification of Tumors: Tumors of the Haematopoietic and Lymphoid Tissues Lyon 2001, 17-44. International Agency for Research on Cancer Press, France. E.S.H.N. Jaffe, H. Stein (Eds.).
22. Gale R.P., Barosi G., Barbui T., Cervantes F., Dohner K., Dupriez B., et al. What are RBC-transfusion-dependence and -independence. Leuk Res 2011, 35:8-11.
23. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
24. Schlenk R.F., Stegelmann F., Reiter A., Jost E., Gattermann N., Hebart V., et al. Pomalidomide in MPN-associated Myelofibrosis with Cytopenia: Results of the Mpnsg 01-09 Study 2003, American Society of Hematology, New Orleans, Blood.